SMMT

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024

Retrieved on: 
Wednesday, May 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Doctor of Philosophy, PFS, Paranal Observatory, Table, License, Summit, Investment, ELCC, Progression-free survival, Research, Intraparenchymal hemorrhage, Immunotherapy, Trial of the century, Webcast, Cohort, Forecasting, PD-1, NGS, TKI, Patient, GRAIL, Brain, SMMT, Neoplasm, EGFR, VEGF, GAAP, Royal institute, Neuro, Lung cancer, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.
  • In January 2024, followed by a presentation at ELCC 2024 in March 2024, Akeso announced updates from its Phase II AK112-201 trial data.
  • Also at ELCC 2024, Summit and Akeso highlighted promising ivonescimab Phase II data in NSCLC patients with brain metastases.
  • Operating cash outflow for the three months ended March 31, 2024 and 2023 was $30.1 million and $13.1 million, respectively.

Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024

Retrieved on: 
Wednesday, April 24, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Summit, SMMT

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens.
  • Summit will host a live webcast of the earnings conference call at 9:00am ET, which will be accessible through our website www.smmttx.com .
  • An archived edition of the session will be available on our website.

Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors

Retrieved on: 
Thursday, April 11, 2024
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Doctor of Philosophy, Genomics, Mostafa Ronaghi, Pyrosequencing, Trauma, Clear Labs, NGS, Senior, Translation, GRAIL, SMMT, Organization, Royal institute, Management

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately.
  • “We are excited to add Dr. Ronaghi to complement our excellent group of current board members,” stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit.
  • As we intend to maximize the potential of ivonescimab, we are excited to add the acumen and expertise that Mostafa can bring to our impressive executive team.”
    Dr. Ronaghi is the Co-Founder and Executive Board Member of Cellanome.
  • “I am very pleased at the opportunity to join Summit’s Board of Directors,” said Dr. Ronaghi.

Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum

Retrieved on: 
Wednesday, April 10, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, SMMT

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the Stifel 2024 Targeted Oncology Forum, which will be held virtually April 16-17, 2024.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the Stifel 2024 Targeted Oncology Forum, which will be held virtually April 16-17, 2024.
  • Dr. Maky Zanganeh, Chief Executive Officer and President, Robert W. Duggan, Chairman and Chief Executive Officer, Manmeet Soni, Chief Operating Officer & Chief Financial Officer, Dave Gancarz, Chief Business & Strategy Officer, and Dr. Allen S. Yang, Chief Medical Officer, will participate in a fireside chat on behalf of our organization surrounding the development of our innovative investigational bispecific antibody, ivonescimab, on Tuesday April 16, 2024 at 2:30pm ET.
  • The presentation will be available live from our website: www.smmttx.com .
  • An archived version will be available on our website following the presentation.

Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer

Retrieved on: 
Tuesday, April 9, 2024
Dhingra, CFO, McKinsey & Company, EY, Health, Agilent Technologies, Bain & Company, ILMN, Growth, Corporate development, DNA, Staff, SMMT, Genome, Accounting, Chartered accountant, SAN, Management

SAN DIEGO, April 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team appointments.

Key Points: 
  • Ankur Dhingra is joining Illumina as Chief Financial Officer (CFO), leading Illumina's financial planning and analysis, accounting, investor relations, internal audit, tax, and treasury functions.
  • Jakob Wedel has been named Chief Strategy and Corporate Development Officer.
  • Wedel joined Illumina in November 2023 as CEO Chief of Staff, leading strategic transformation initiatives.
  • They succeed Goswami, who held both the CFO and Chief Strategy and Corporate Development Officer roles since early 2023.

Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024

Retrieved on: 
Friday, March 22, 2024
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, SMMT, Intraparenchymal hemorrhage, Sun, EGFR, Central European Time, Metastasis, ELCC, Progression-free survival, Anaplastic lymphoma kinase, Constipation, Brain, Drug, HKEX, Safety, Anemia, Phase, Summit, TKI, Time in Europe, PFS, ALK, Pharmaceutical industry

The first poster, “Intracranial Activity of Ivonescimab Alone or in Combination with Platinum Doublet Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases” includes data from patients with asymptomatic brain metastases at baseline.

Key Points: 
  • The first poster, “Intracranial Activity of Ivonescimab Alone or in Combination with Platinum Doublet Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases” includes data from patients with asymptomatic brain metastases at baseline.
  • This analysis consisted of the 35 patients with advanced or metastatic NSCLC who had asymptomatic brain metastases at baseline; 28 patients were treated with ivonescimab plus chemotherapy in AK112-201, and seven patients were treated with monotherapy ivonescimab in AK112-202.
  • Patients across both cohorts experienced an intracranial response rate of 34%, and eight patients (23%) experienced a complete response by RANO criteria.
  • The most frequent TEAEs were anemia and decreased neutrophil counts in squamous patients and anemia and constipation in non-squamous patients.

Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, SMMT, Sun, EGFR, Central European Time, ELCC, NSCLC, Anaplastic lymphoma kinase, Drug, HKEX, Safety, Phase, Summit, TKI, Time in Europe, ALK, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2024 European Lung Cancer Congress (ELCC 2024) in Prague, Czech Republic.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2024 European Lung Cancer Congress (ELCC 2024) in Prague, Czech Republic.
  • Two posters featuring updated ivonescimab data will be displayed on Friday, March 22 from 12:00 to 12:45pm Central European Time.
  • The first poster, “Intracranial Activity of Ivonescimab Alone or in Combination with Platinum Doublet Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases” includes data from patients with asymptomatic brain metastases at baseline.
  • These patients were enrolled in either AK112-202 (NCT04900363), in which ivonescimab is delivered as monotherapy, or AK112-201 (NCT04736823), in which ivonescimab is delivered in combination with platinum doublet chemotherapy, both of which are Phase II clinical trials for patients with advanced or metastatic NSCLC.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT

Retrieved on: 
Thursday, March 7, 2024
LLP, News, Pomerantz, Sale, Summit, SMMT, Cryptocurrency

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT).

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT).
  • The investigation concerns whether Summit and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On February 20, 2024, Summit reported its financial results for the fourth quarter and full year 2023 and “provide[d] an update on its operational progress”.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT

Retrieved on: 
Wednesday, February 28, 2024
Prior, LLP, News, Pomerantz, Sale, Summit, SMMT, Cryptocurrency

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT).

Key Points: 
  • NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT).
  • The investigation concerns whether Summit and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On February 20, 2024, Summit reported its financial results for the fourth quarter and full year 2023 and “provide[d] an update on its operational progress”.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference

Retrieved on: 
Tuesday, March 5, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Barclays, SMMT, Conference

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the Barclays 26th Annual Global Healthcare Conference, which will be held in Miami Beach, FL, from March 12-14, 2024.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the Barclays 26th Annual Global Healthcare Conference, which will be held in Miami Beach, FL, from March 12-14, 2024.
  • Dr. Maky Zanganeh, Chief Executive Officer and President, and Robert W. Duggan, Chairman and Chief Executive Officer, will present on behalf of our organization and provide details regarding the development of our innovative investigational bispecific antibody, ivonescimab, on Tuesday March 12, 2024 at 2:35pm ET.
  • They will be joined by Manmeet Soni, Chief Operating Officer; Dave Gancarz, Chief Business & Strategy Officer; and Dr. Allen S. Yang, Chief Medical Officer.
  • An archived version will be available on our website following the presentation.